Skip to main content

DaVita Value Stock - Dividend - Research Selection


ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q4 2023 Update

Berkshire Hathaway's stock portfolio sees an 11% increase in Q4 2023, with Apple, Bank of America, and American Express leading the top positions. Explore more here.

DaVita Stock Is Having Its Best Day in Years. Volumes Are Improving After Covid-19.

DaVita stock was climbing Wednesday after the dialysis provider’s fourth-quarter financials came in above Wall Street’s consensus. DaVita stock was surging 10% to $124.39, which would be the stock’s highest close since September 2021, and largest percentage increase since May 9, 2023, when a strong quarter sent shares soaring. DaVita posted a “solid finish,” to 2023, and provided even better 2024 guidance, Truist Securities analyst David MacDonald wrote in a research note.

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

DaVita (DVA) Q4 2023 Earnings Call Transcript

DVA earnings call for the period ending December 31, 2023.

DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita Inc (DVA) Reports Solid Financial Performance Amid Operational Challenges

Comprehensive Earnings Summary for Q4 and Full Year 2023

DaVita Inc. 4th Quarter 2023 Results

DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2023.

DaVita Inc. (DVA) Q4 2023 Earnings Call Transcript

DaVita Inc. (NYSE:NYSE:DVA) Q4 2023 Earnings Conference Call February 13, 2024 5:00 PM ETCompany ParticipantsNic Eliason - Group Vice President, Investor...

DaVita gains after co says expects strong 2024 profit

DaVita forecast 2024 profitabove Wall Street estimates on Tuesday on anticipated strongdemand for its kidney dialysis services, sending its shares up4.8% after the bell. The...

DaVita Inc. stock underperforms Tuesday when compared to competitors

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.